The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Early Detection Of Melanoma Metastases Using MicroRNA As Novel Biomarkers
Funder
National Health and Medical Research Council
Funding Amount
$109,363.00
Summary
The use of a minimally invasive blood test to measure the circulating levels of melanoma-specific miRNAs may provide a rapid assessment for clinical management of the disease during dissemination of the tumour. This work has the potential to provide new prognostic markers for melanoma as well as to identify new gene targets for the design of rational therapies to treat this disease.
Tissue factor is a central and major player in the clotting process. It exists in both active and inactive forms. The active form initiates clot formation. How it gets activated is one of the most important unanswered questions in this area of research. Our aim is to discover tissue factorÍs mechanism of activation. The outcome will provide more specific targets for therapeutic drug development for cardiovascular disease, strokes and deep venous thrombosis.
Transcriptional Control Of Peripheral T Cell Differentiation During Pathogen Infection And Autoimmunity
Funder
National Health and Medical Research Council
Funding Amount
$92,314.00
Summary
White blood cells, specifically helper and killer T cells, play an important role in fighting infection. They are tightly regulated and if not properly controlled can lead to aggressive autoimmune diseases such as diabetes and multiple sclerosis. My studies will elucidate the mechanisms behind the regulation of T cells at steady-state and during disease. Insights gained from this project will have implications for the design of new approaches to combat infectious and autoimmune diseases.
BDNF Genotype And Emotional Memory In Post-traumatic Stress Disorder
Funder
National Health and Medical Research Council
Funding Amount
$108,902.00
Summary
This project addresses the question of why some people develop PTSD following trauma and others don’t. It will assess the influence of genetics (specifically a genotype that influences Brain Derived Neurotrophic Factor) on emotional memory processes as distressing emotional memories are a core symptom of PTSD. If we find that people with a particular genetic profile have a greater risk of developing intrusive memories after trauma, this will help us better target treatment for those individuals.
Investigation Into Oral Cancer In Non-drinking And Non-smoking Females
Funder
National Health and Medical Research Council
Funding Amount
$109,358.00
Summary
There has been an increase incidence of oral cancer in female non-drinkers, non-smokers. The five year survival following diagnosis can be as low as 15-50% as most cancers are advanced at the time of discovery.Precancerous and cancerous oral lesions may mimic any number of benign oral lesions, and as such may be left without investigation and treatment until well advanced. Further investigations into the cause of oral cancer other than smoking and alcohol will aid in management.
The Importance Of RUNX3 In Preventing Gastrointestinal Diseases And Tumour Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Stomach cancer is the second leading cause of cancer-related deaths. It is estimated that in 2010, more than 1 million people will die of stomach cancer with an increase of 19%. Studies have revealed that RUNX3 has the ability to suppress the growth of stomach cancer. However the role of RUNX3 in preventing metastasis is yet unknown. Therefore, an understanding of the factors that govern metastasis will inform the design of effective therapies to prevent mortality which is high for this disease.
Targeted Molecular Therapies And Predictive Biomarkers In A Novel Orthotopic Xenograft Model Of Oesophageal Carcinoma
Funder
National Health and Medical Research Council
Funding Amount
$120,253.00
Summary
Oesophageal cancer is the most rapidly increasing malignancy in Western society. This disease often presents in advanced stages with poor response to established medical and surgical therapies. Our aim is to develop a novel mouse model of oesophageal cancer, allowing us to tailor cancer-inhibiting molecular treatments to individual patients by predicting therapeutic success or resistance with the use of cellular markers identified in our animal mode.